Medical Supplies for Home
#1001177399 | Mfg #20377 | Clinical Laboratory

Rapid Test Kit Sofia® 2 Fluorescence Immunoassay (FIA) Flu + SARS Antigen FIA Nasal Swab Sample 25 Tests

TEST KIT, SOFIA FLU & SARS ANTIGEN FIA ASSY (25/KT 12KT/CS)
Rapid Test Kit Sofia® 2 Fluorescence Immunoassay (FIA) Flu + SARS Antigen FIA Nasal Swab Sample 25 Tests

For use on Sofia 2 analyzers ONLY - test cannot be run on a Sofia 1 analyzer; reach out to your account manager with any analyzer questions or requests

Product Specifications

MSFH #
1001177399
Manufacturer #
Sofia® 2, 20377, Quidel
Brand
(25) X 120 µL Fixed Volume Pipettes, (25) Sterile Nasal Swabs, (25) Ampoules of Reagent Solution, (25) Reagent Tubes, (25) Individually Packaged Test Cassettes, Rapid Test Kit, United States, Flu + SARS Positive Control Swab
Manufacturer
Negative Control Swab
Country of Origin
Package Insert
Application
Quick Reference Instructions
Contents 1
QC Card
For Use With
For use with Sofia 2 Fluorescent Immunoassay Analyzer
Number of Tests
25 Tests
Product Dating
MSFH Acceptable Dating: we will ship >= 30 days
Reading Type
Machine Read
Sample Type
Nasal Swab Sample
Test Format
Cassette Format
Test Name
Flu + SARS Antigen FIA
Test Type
Fluorescence Immunoassay (FIA)
Time to Results
15 Minute Results
UNSPSC Code
41116144

Description

Product ships with minimum 30 days dating

Sofia 2 Flu + SARS Antigen FIA is for use under an FDA EUA: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations

Emergency use of this test is limited to Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high, moderate or waived complexity tests

This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner

The Sofia 2 Flu + SARS FIA is intended to be used with direct nasal or nasopharyngeal swabs and is not validated for use with viral transport media

The test is intended for use in the simultaneous rapid in vitro detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus nucleocapsid protein antigen , but does not differentiate, between SARS-CoV and SARS-CoV-2 viruses and is not intended to detect influenza C antigens

Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status

Positive results do not rule out bacterial infection or co-infection with other viruses

Laboratories within the United States and its territories are required to report all SARS-CoV-2results to the appropriate public health authorities

Negative results do not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions; negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19

Negative SARS-CoV-2 results, from patients with symptom onset beyond five days, should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed

The Sofia 2 Flu + SARS Antigen FIA is intended for use on the Sofia 2 only and by medical professionals or trained operators who are proficient in performing tests using the Sofia 2 Instrument; the Sofia 2 Flu + SARS Antigen FIA test is only for use under the Food and Drug Administration’s Emergency Use Authorization

Accurate detection with direct samples

Results in 15 minutes

12-month shelf life from date of manufacture

This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner

Room temperature storage

Customer Reviews

No reviews yet. Be the first to review this product.

Write a Review

Used to verify your review and never shown to other customers.